Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Running

biosim m2m BioSim M2M: Molecules to Medicine

Coordinator
Biosimulytics Limited, Ireland
Runs
1 September 2023 to 28 February 2026
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190181387

What the project is doing

In the project's own words, from its summary on CORDIS.

BioSimulytics has developed breakthrough technology combining quantum physics, computational chemistry, machine learning, and high-performance computing to boost the success rates of pharmaceutical R&D. The BioSimulytics invention (patent EP3948877A1), is being applied to crystal structure prediction (CSP) for determining the most stable crystal structure or polymorph of a drug compound, as well as the most stable binding poses in protein-ligand complexes.

Existing state-of-the-art techniques for polymorph analysis require long and painstaking experimentation by material scientists with uncertain results (<1% success rates). BioSim M2M will reduce the time to find the most stable crystal structures of a molecule from 3 months to 3 weeks and reduce candidate experiments from 400 to 40. As a result, BioSim M2M will contribute to the Pharmaceutical Strategy for Europe by helping to ensure that patients have access to high quality, effective, and safe medicines.

Who is involved

OrganisationCityCountryRole
Biosimulytics LimitedDublinIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI